FDA panel recommends mRNA flu vaccine for older adults
A first-of-its-kind flu shot is a step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval. The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older.  Moderna is seeking…
Original Source
Read the full article at Thehill →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.